BAJAJ BROKING

Notification close image
No new Notification messages
card image
🚨 TRADING HOLIDAY 🚨
The NSE and BSE will remain closed for trading and settlement on Wednesday, August 27, 2025, on account of Ganesh Chaturthi.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

0

524414

NORRIS

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

NORRIS MEDICINES LTD. Share Price Update

As of the latest trading session, NORRIS MEDICINES LTD. share price is currently at ₹ 16.3, which is up by ₹ 0.29 from its previous closing. Today, the stock has fluctuated between ₹ 16.00 and ₹ 16.78. Over the past year, NORRIS MEDICINES LTD. has achieved a return of 15.85 %. In the last month alone, the return has been 0.06 %. Read More...

Investment Returns

Over 1 Month 0.06% Over 3 Months -20.63% Over 6 Months -20.00% Over 1 Year 15.85%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

NORRIS MEDICINES LTD. fundamentals


  • Market cap (Cr)

  • P/E Ratio (TTM)

  • Beta

  • Book Value / share

  • Return on equity

    %

  • EPS (TTM)

  • Dividend yield

    %

  • Net profit/quarter (Cr)

info icon alternate text
  • Market cap (Cr)

    16.30

  • P/E Ratio (TTM)

    -13.56

  • Beta

    0.20

  • Book Value / share

    -14.78

  • Return on equity

    0.00%

  • EPS (TTM)

    0.00

  • Dividend yield

    %

  • Net profit/quarter (Cr)

    -0.31

info icon alternate text

NORRIS MEDICINES LTD. Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars JUN 2025 (Values in Cr)
Revenue 1.46
Operating Expense 1.79
Net Profit -0.31
Net Profit Margin (%) -21.23
Earnings Per Share (EPS) -0.31
EBITDA -0.08
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Revenue 2.72
Operating Expense 2.94
Net Profit -0.23
Net Profit Margin (%) -8.45
Earnings Per Share (EPS) -0.23
EBITDA 0.12
Effective Tax Rate (%) -35.29
Particulars DEC 2024 (Values in Cr)
Revenue 1.11
Operating Expense 1.39
Net Profit -0.28
Net Profit Margin (%) -25.22
Earnings Per Share (EPS) -0.28
EBITDA -0.03
Effective Tax Rate (%) 0.00
Particulars SEP 2024 (Values in Cr)
Revenue 1.27
Operating Expense 1.63
Net Profit -0.36
Net Profit Margin (%) -28.34
Earnings Per Share (EPS) -0.36
EBITDA -0.14
Effective Tax Rate (%) 0.00
Particulars JUN 2024 (Values in Cr)
Revenue 0.72
Operating Expense 1.10
Net Profit -0.37
Net Profit Margin (%) -51.38
Earnings Per Share (EPS) -0.37
EBITDA -0.15
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Revenue 5.82
Operating Expense 7.06
Net Profit -1.24
Net Profit Margin (%) -21.30
Earnings Per Share (EPS) -1.24
EBITDA -0.19
Effective Tax Rate (%) -5.08
Particulars MAR 2024 (Values in Cr)
Revenue 5.64
Operating Expense 6.76
Net Profit -1.19
Net Profit Margin (%) -21.09
Earnings Per Share (EPS) -1.19
EBITDA -0.16
Effective Tax Rate (%) -8.18
Particulars MAR 2023 (Values in Cr)
Revenue 8.36
Operating Expense 9.57
Net Profit -1.75
Net Profit Margin (%) -20.93
Earnings Per Share (EPS) -1.75
EBITDA 0.94
Effective Tax Rate (%) -47.05
Particulars MAR 2022 (Values in Cr)
Revenue 9.44
Operating Expense 11.65
Net Profit -3.26
Net Profit Margin (%) -34.53
Earnings Per Share (EPS) -3.26
EBITDA -0.04
Effective Tax Rate (%) -49.54
Particulars MAR 2021 (Values in Cr)
Revenue 12.25
Operating Expense 16.29
Net Profit -4.96
Net Profit Margin (%) -40.48
Earnings Per Share (EPS) -4.96
EBITDA -1.69
Effective Tax Rate (%) -24.31
Particulars MAR 2024 (Values in Cr)
Book Value / Share -13.73
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -2.84
Particulars MAR 2023 (Values in Cr)
Book Value / Share -12.54
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin 11.24
Particulars MAR 2022 (Values in Cr)
Book Value / Share -10.77
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -0.53
Particulars MAR 2021 (Values in Cr)
Book Value / Share -7.49
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -13.88
Particulars MAR 2020 (Values in Cr)
Book Value / Share -2.49
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -26.20
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.03
Total Assets 14.18
Total Liabilities 14.18
Total Equity -13.63
Share Outstanding 10000700
Price to Book Ratio -0.99
Return on Assets (%) -8.36
Return on Capital (%) -15.03
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.02
Total Assets 13.68
Total Liabilities 13.68
Total Equity -12.44
Share Outstanding 9925750
Price to Book Ratio -0.83
Return on Assets (%) -12.78
Return on Capital (%) -19.52
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.01
Total Assets 14.19
Total Liabilities 14.19
Total Equity -10.69
Share Outstanding 9925750
Price to Book Ratio 0.00
Return on Assets (%) -22.99
Return on Capital (%) -31.43
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.02
Total Assets 19.78
Total Liabilities 19.78
Total Equity -7.43
Share Outstanding 9925750
Price to Book Ratio -0.87
Return on Assets (%) -25.07
Return on Capital (%) -61.31
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 0.06
Total Assets 20.55
Total Liabilities 20.55
Total Equity -2.46
Share Outstanding 9925750
Price to Book Ratio -1.13
Return on Assets (%) -13.82
Return on Capital (%) -22.7
Particulars MAR 2024 (Values in Cr)
Net Income -1.18
Cash from Operations 0.16
Cash from Investing 0.05
Cash from Financing -0.20
Net change in Cash 0.01
Free Cash Flow 0.17
Particulars MAR 2023 (Values in Cr)
Net Income -1.74
Cash from Operations 1.19
Cash from Investing -0.02
Cash from Financing -1.17
Net change in Cash 0.00
Free Cash Flow 1.22
Particulars MAR 2022 (Values in Cr)
Net Income -3.26
Cash from Operations -1.00
Cash from Investing -0.08
Cash from Financing 1.09
Net change in Cash 0.00
Free Cash Flow -0.95
Particulars MAR 2021 (Values in Cr)
Net Income -4.96
Cash from Operations 1.11
Cash from Investing -0.06
Cash from Financing -1.09
Net change in Cash -0.04
Free Cash Flow 1.20
Particulars MAR 2020 (Values in Cr)
Net Income -2.84
Cash from Operations -2.88
Cash from Investing 0.00
Cash from Financing 2.85
Net change in Cash -0.01
Free Cash Flow -2.80
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 33.30 13.59 1.82 255.19 30.00 / 69.75
BLISS GVS PHARMA LTD 159.00 15.73 1.59 1677.41 105.05 / 190.65
CIPLA LTD 1601.10 23.98 4.14 129329.50 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 323.75 9.12 2.62 952.83 219.00 / 449.00
GLAXOSMITHKLINE PHARMA LT 2799.20 50.08 24.30 47420.14 1924.30 / 3515.95
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 33.30 18.10 5.26 255.19 30.00 / 69.75
AMRUTAJAN HEALTH LTD 708.10 37.55 6.26 2047.16 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8297.10 98.09 26.92 20742.75 6222.35 / 10653.05
BLISS GVS PHARMA LTD 159.00 23.77 1.58 1677.41 105.05 / 190.65

NORRIS MEDICINES LTD. Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
16.30 1.87 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 16.40
  • 26 Days 17.00
  • 10 Days 16.70
  • 50 Days 17.40
  • 12 Days 16.80
  • 100 Days 17.80
  • 20 Days 16.90
  • 200 Days 17.90
16.11 PIVOT

First Support

15.39

First Resistance

16.73

Second Support

14.77

Second Resistance

17.45

Third Support

14.05

Third Resistance

18.07

RSI

40.97

ADX

17.29

MACD

-0.28

Williams % R

-84.62

Commodity Channel Index (CCI)

-134.60

Date

2025-08-25

Week

1706.00

Same Day

1867.00

Month

972.00

1 Year

0.20

3 Year

0.11

Over 1 Month

0.06%

down

Over 1 Year

15.85%

down

Over 3 Months

-20.63%

down

Over 3 Years

19.56%

down

Over 6 Months

-20.00%

down

Over 5 Years

26.80%

down

Transparent Pricing, 360° Services

Choose a plan that best suits your goals & needs.

greenshadow greenshadow redshadow pricing-pack Freedom Pack
₹20/order 14.99% p.a. MTF
tick Expert Stock Research tick Online Customer Support

Subscription Charge : FREE

greenshadow greenshadow redshadow pricing-pack

Professional Pack

₹10/order 11.99% p.a. MTF
tick Expert Stock Research tick Online Customer Support

Subscription Charge : 2500 Yearly

50% Brokerage Savings
greenshadow greenshadow redshadow pricing-pack

Signature

0.2% 11.99% p.a. MTF
tick Dedicated Relationship Manager tick Customised Brokerage Support tick Expert Stock Research tick Experienced Dealer Support

NORRIS MEDICINES LTD. shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Name Shares Category

News

Left Arrow
Right Arrow

NORRIS MEDICINES LTD. corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

NORRIS MEDICINES LTD. Share Price

Norris Medicines Limited was established in September, 1990 as a small scale unit at GIDC Estate, Ankleshwar to manufacture non sterile dosage e.g. tablets, capsules, Liquid Orals, Copical ointments. The Company was subsequently converted into Public Limited Company on March 7, 1992. The unit expanded to manufacture Sterile dosage in form of Ampoules & Vials.

The Company got into the business in the year 1990. Commercial production of the formulation unit commenced in Nov.'91. The production unit expanded to manufacture Sterile dosage in form of Ampoules & Vials. The project commence in March 1992. Thereafter, the Company came out with a Public Issue aggregating Rs. 5 Crore in December, 1993 to expand its existing capacity for tablets, capsules, etc, besides diversifying into bulk drugs and setting up an injectables unit. The project costing Rs 14.21 Crore was financed through loans and equity, which got completed in 1995.

In 2006, the Company launched Diabetic & Cardiac products; launched Dental product in 2007; launched New Molecule Tolperisone with Paracetamol tablet in 2012; in 2013, it extended Anti malarial range with Artemether Lumefantrine tablet & dry syrup. During the year 2013-14, the Company undertook the upgradation of Sterile Injectable Plant.

The Company is one of the leading Indian manufacturers of Injections and Medicinal formulations. The Company is engaged into Health Care Industry and operate 2 plants situated at GIDC, Ankleshwar, Gujarat. Both plants of the Company are WHO GMP approved. At present, it has renovated the Sterile Injectable Plant and with this the plant is now as per international standards.

Parent organization Indian Private
NSE symbol [-]
Founded 1990
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Norris Medicines Ltd?

Answer Field

Norris Medicines Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 16.30 as on Aug 26 2025 03:24 PM.

What is the Market Cap of Norris Medicines Ltd Share?

Answer Field

The market cap of Norris Medicines Ltd for NSE ₹ 0.00 & for BSE ₹ 16.30 as on Aug 26 2025 03:24 PM.

What is the 52 Week High and Low of Norris Medicines Ltd?

Answer Field

The 52 Week High and Low of Norris Medicines Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 27.74 and ₹ 13.20.

What is 1 year return for Norris Medicines Ltd?

Answer Field

The 1 year returns on the stock has been 15.85%.

What is the P/E Ratio of Norris Medicines Ltd Share?

Answer Field

As on Aug 26 2025 03:24 PM the price-to-earnings (PE) ratio for Norris Medicines Ltd share is -13.56.

What is the PB ratio of Norris Medicines Ltd Share?

Answer Field

As on Aug 26 2025 03:24 PM, the price-to-book (PB) ratio for Norris Medicines Ltd share is -14.78.

How to Buy Norris Medicines Ltd Share?

Answer Field

You can trade in Norris Medicines Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Norris Medicines Ltd Share on Bajaj Broking App?

Answer Field

To buy Norris Medicines Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Norris Medicines Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

close-image

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
close-image

Get Free Demat Account*

+91